GLP-1 and PCOS: What the Fertility and Weight-Loss Evidence Shows

Polycystic ovary syndrome (PCOS) and obesity interact in both directions — excess weight worsens PCOS symptoms, and PCOS's own hormonal and insulin-resistance profile makes weight loss harder through diet and exercise alone. That's made GLP-1s a genuine subject of PCOS-specific research, separate from the general obesity trials. Here's what randomized, controlled data actually shows for this population.

The randomized trial

A Phase 3, randomized, double-blind, placebo-controlled trial tested liraglutide 3 mg specifically in women with PCOS and obesity: 82 participants, 55 assigned to liraglutide and 27 to placebo, both arms combined with lifestyle intervention, followed for 32 weeks¹. Because it's placebo-controlled and randomized — not an observational comparison — it's a stronger basis for a causal read on both weight and hormonal outcomes than a cohort study would be.

The weight-loss and hormonal results

Body weight fell 5.7% (±0.75) on liraglutide versus 1.4% (±1.09) on placebo by week 32, and more than half of the liraglutide group (25 of 44 evaluable participants) reached at least 5% weight loss, versus 5 of 23 on placebo¹. On the hormonal side — often the more clinically relevant outcome for PCOS specifically, since androgen excess drives many of the syndrome's symptoms — the trial found the free androgen index (a standard marker of circulating testosterone activity) "significantly reduced with LIRA 3 mg compared with the PL where the mean FAI slightly increased"¹. GI side effects were common and roughly consistent with what's reported across the GLP-1 class generally: 58.2% of the liraglutide group reported a GI adverse event versus 18.5% on placebo¹ — see GLP-1 side effects: what the STEP and SURMOUNT trials actually reported for how that compares to the newer, more commonly prescribed GLP-1s.

What the broader pooled evidence adds

A 2024 meta-analysis pooling four randomized controlled trials — 176 total participants, with liraglutide making up 58% and semaglutide 13% of the studied population — found statistically significant improvements beyond weight alone: BMI fell by a mean difference of -2.42 (95% CI, -3.10 to -1.74, P<0.00001), waist circumference by -5.16 cm (95% CI, -6.11 to -4.21, P<0.00001), and total testosterone by a mean difference of -1.33 (95% CI, -2.55 to -0.12, P=0.03)². Not every metabolic marker moved: HOMA-IR, a standard measure of insulin resistance, showed no statistically significant difference (P=0.35), nor did total cholesterol (P=0.15)² — a useful reminder that GLP-1 treatment in PCOS improved weight and androgen markers in the pooled data, but didn't uniformly move every metabolic marker researchers checked. The review's own conclusion was measured rather than sweeping, describing the results as signifying GLP-1s' "viability as a favourable treatment option for managing PCOS symptoms in women living with obesity"² — supportive, not definitive.

What this evidence doesn't establish

Neither study directly measured fertility outcomes like ovulation rate, conception, or live birth — they measured weight, BMI, and hormonal markers that are mechanistically linked to fertility in PCOS (androgen excess and insulin resistance both interfere with ovulation), but that's an indirect case, not a trial that tracked pregnancy outcomes directly. If fertility specifically, not just weight or hormone levels, is your goal, that distinction matters for the conversation with your prescriber. It's also worth flagging plainly: current GLP-1 labels carry specific guidance on stopping the drug before a planned pregnancy, covered in full in GLP-1 and pregnancy or breastfeeding: what the labels actually say — a PCOS patient using a GLP-1 partly to improve fertility odds needs to plan around that washout window, not treat the drug as something to stay on through conception.

The cost angle worth knowing

Both key trials here used liraglutide, not the newer, more commonly prescribed semaglutide or tirzepatide — and liraglutide is meaningfully cheaper as a result of being older and further from patent exclusivity. If PCOS-specific hormonal improvement, not maximum weight loss, is your primary goal, that's a legitimate reason to discuss whether the older, less expensive drug is a reasonable starting point rather than defaulting to the newest option — see semaglutide vs liraglutide: is the older, cheaper GLP-1 worth it? for that direct cost-and-efficacy comparison.

Where this fits your provider decision

PCOS involves a specific hormonal and metabolic profile that a generic weight-loss-focused intake may not ask about in enough depth — ask directly whether a prospective program's prescribers have experience treating PCOS specifically, not just obesity generally. See how we weigh real medical oversight in our Value Score methodology, and compare pricing on our semaglutide price board.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.